AI Portfolio Summary
In 2026 Q1, Royalty Pharma Sub-Manager, LLC maintained a portfolio of 4 distinct positions. The most significant new addition to the portfolio was CYTOKINETICS, INC, which now represents 36.36% of the total fund value.
Total Positions
4
Quarter
2026 Q1
Top Holding
CYTK (36.4%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-4 of 4
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CYTK
CYTOKINETICS, I...
|
Unknown | 36.36% | — |
#1
Prev: #—
|
9.5 | 980,392 | no change |
NEW
|
980,392 | $62,294,108 |
$65.91
+1.2%
|
2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 (Est.) | ||
|
BCAX
ZENAS BIOPHARMA...
|
Unknown | 26.77% | — |
#2
Prev: #—
|
9.0 | 1,263,150 | no change |
NEW
|
1,263,150 | $45,864,977 |
$19.89
+7.9%
|
2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 (Est.) | ||
|
BHVN
BIOHAVEN LTD
|
Unknown | 19.35% | — |
#3
Prev: #—
|
8.5 | 2,936,507 | no change |
NEW
|
2,936,507 | $33,153,164 |
$8.46
+15.8%
|
2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 (Est.) | ||
|
BCRX
BIOCRYST PHARMA...
|
Unknown | 17.51% | — |
#4
Prev: #—
|
8.0 | 3,846,154 | no change |
NEW
|
3,846,154 | $30,000,001 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 (Est.) |
Showing 1-4 of 4 holdings